Methods: We performed a literature search in MEDLINE, EMBASE, Cochrane library, and the ASH website up to September, 2015 by two independent authors according to PRISMA guideline. We included only randomized clinical trials comparing eltrombopag or romiplostim versus placebo. Random-effects model was used to estimate pooled Odds Ratio (OR).
Results: A total of eight trials including 834 participants were included in the analysis. There was no significant difference of grade 3 or higher adverse events between placebo and treatment group (OR=1.01, CI 0.57-1.78). Thromboembolism (OR=0.59 CI 0.20-1.73), elevated ALT (OR=0.68 CI 0.26-1.74), headache (OR=1.26, CI 0.90-1.78), nausea (OR=0.82 CI 0.43-1.55), or fatigue (OR=1.13 CI 0.65-1.91) did not show a significant difference between groups, either. Clinical response, which is defined as platelets ≥50,000/μL at least once on treatment was significantly better in treatment group than in placebo group (OR=0.10 CI 0.07-0.15). Bleeding symptoms (WHO Grades 1-4) were significantly more frequent in the placebo group (OR=1.6, CI 1.14-2.24) during treatment.
Conclusions: Although several studies have suggested clinically significant treatment-related adverse events, such as thromboembolism, this meta-analysis showed that thrombopoietin receptor agonists are safe, well-tolerated, and effective in patients with previously treated chronic ITP.
To cite this abstract:Yamada, Y; Fujii, T; Cromwell, C; Shapira, I . SAFETY AND EFFICACY OF THROMBOPOIETIN RECEPTOR AGONISTS IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Abstract published at Hospital Medicine 2017, May 1-4, 2017; Las Vegas, Nev. Abstract 102. Journal of Hospital Medicine. 2017; 12 (suppl 2). https://www.shmabstracts.com/abstract/safety-and-efficacy-of-thrombopoietin-receptor-agonists-in-patients-with-previously-treated-chronic-immune-thrombocytopenia-a-systematic-review-and-meta-analysis/. Accessed January 20, 2020.